Abiraterona en cáncer de próstata hormono-sensible metastásico

15 / 32

RESULTS: OVERALL SURVIVAL
Low Risk High Risk
ADT +AAP
ADT
ADT + AAP
ADT
82.4%
78% 64.7 %
45 %
OS - 4.4%
HR 0.66 (0.44-0.98)
p=0.041
OS – 19.7%
HR 0.54 (0.41-0.70)
p<0.001
RESULTS: OVERALL SURVIVAL
Low Risk High Risk
ADT +AAP
ADT
82.4%
78% 64.7 %
45 %
OS - 4.4%
HR 0.66 (0.44-0.98)
p=0.041
OS
HR
p<0